STipe Therapeutics
Aarhus
About STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2019)
- Website: stipetherapeutics.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/stipe-therapeutics-145619 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.